Aqua Bio Technology Bilan de santé

Santé financière contrôle des critères 0/6

Aqua Bio Technology possède un total de capitaux propres de NOK7.7M et une dette totale de NOK20.3M, ce qui porte son ratio d'endettement à 264.7%. Son actif total et son passif total sont NOK66.7M et de NOK59.0M.

Informations clés

264.7%

Ratio d'endettement

NOK 20.33m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	NOK 727.44k
Fonds propres	NOK 7.68m
Total du passif	NOK 58.99m
Total des actifs	NOK 66.67m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More Shares

Jan 20

Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?

Dec 30

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ABTEC ( NOK11.1M ) ne couvrent pas ses passifs à court terme ( NOK33.6M ).

Passif à long terme: Les actifs à court terme de ABTEC ( NOK11.1M ) ne couvrent pas ses passifs à long terme ( NOK25.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de ABTEC ( 255.2% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de ABTEC est passé de 1.7% à 264.7% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: Données insuffisantes pour déterminer si ABTEC dispose de suffisamment de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: Données insuffisantes pour déterminer si ABTEC dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.

Aqua Bio Technology Bilan de santé

Santé financière contrôle des critères 0/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

New major risk - Shareholder dilution

New major risk - Share price stability

Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024

Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.

New major risk - Financial data availability

New major risk - Share price stability

Aqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025

New minor risk - Financial data availability

Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.

Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million.

Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.

New major risk - Shareholder dilution

Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic Formulations

New minor risk - Shareholder dilution

Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in funding

New major risk - Share price stability

Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in funding

Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.

Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023

Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023

No independent directors

Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

No independent directors

Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UK

Chief Executive Officer recently bought kr55k worth of stock

Insider recently sold kr1.9m worth of stock

Director recently bought kr57m worth of stock

Aqua Bio Technology ASA Announces Strategic Partnership with DCP Dermoscience

Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Moana Active Skincare Limited for New Zealand and Australia

Aqua Bio Technology ASA Signs an Distribution Agreement with Galaxa Pharma Aps

Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Cosmed Beauty AS

Aqua Bio Technology ASA to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: kr9.20

The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More Shares

Director recently bought kr141k worth of stock

Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?

Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies of 6 Products from the Product Series Balance & Vitality

Aqua Bio Technology Asa: Hydrafacial Has Entered into Partnership with Restorsea - Conversion Lab Launches Veritas Md Platform

Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP.

Aqua Bio Technology ASA Expects to Enter into Three-Year Agreement for the Distribution of Moana Products in New Zealand and Australia

Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies by Nordic Beauty

Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million.

New 90-day high - kr8.35

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines